Sou Hu Cai Jing·2025-08-17 17:53Trading Information Summary - On August 15, 2025, the main capital inflow for Lizhu Group was 39.34 million yuan, while retail and speculative capital saw outflows of 28.72 million yuan and 10.62 million yuan respectively [1][3]. Company Announcement Summary - Lizhu Group received the acceptance notice from the National Medical Products Administration for the domestic production registration of JP-1366 tablets, an innovative potassium ion competitive acid blocker (P-CAB) for treating gastroesophageal reflux disease [1][3]. - The clinical study for JP-1366 included 362 patients and demonstrated that its efficacy in esophageal mucosal healing was non-inferior to that of the comparator drug, Naisan, while significantly improving symptoms such as heartburn and reflux [1][3]. - Cumulative R&D expenses for JP-1366 reached approximately 185.21 million yuan as of the announcement date [1]. - According to IQVIA data, the domestic terminal sales for P-CAB are projected to be approximately 1.25 billion yuan in 2024, reflecting a year-on-year growth of 81.22%, with Q1 2025 sales estimated at around 394.35 million yuan, also showing an 81.63% increase year-on-year [1].